Prudential PLC Lowers Holdings in Amgen Inc. $AMGN

Prudential PLC decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 5.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,965 shares of the medical research company’s stock after selling 2,393 shares during the quarter. Prudential PLC’s holdings in Amgen were worth $14,063,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Deseret Mutual Benefit Administrators raised its stake in Amgen by 1.6% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 3,606 shares of the medical research company’s stock valued at $1,180,000 after buying an additional 57 shares during the last quarter. Argent Advisors Inc. raised its stake in Amgen by 1.7% during the fourth quarter. Argent Advisors Inc. now owns 4,782 shares of the medical research company’s stock valued at $1,565,000 after buying an additional 82 shares during the last quarter. Vise Technologies Inc. raised its stake in Amgen by 66.4% during the fourth quarter. Vise Technologies Inc. now owns 19,503 shares of the medical research company’s stock valued at $6,384,000 after buying an additional 7,779 shares during the last quarter. Daiwa Securities Group Inc. raised its stake in Amgen by 1.4% during the fourth quarter. Daiwa Securities Group Inc. now owns 238,742 shares of the medical research company’s stock valued at $78,143,000 after buying an additional 3,249 shares during the last quarter. Finally, Sittner & Nelson LLC raised its stake in Amgen by 1.5% during the fourth quarter. Sittner & Nelson LLC now owns 7,382 shares of the medical research company’s stock valued at $2,416,000 after buying an additional 106 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.85% of the company’s stock.

Amgen Stock Up 1.2%

Amgen stock opened at $349.58 on Friday. The stock has a market cap of $188.67 billion, a PE ratio of 24.33, a price-to-earnings-growth ratio of 3.47 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The stock has a fifty day moving average of $341.35 and a 200 day moving average of $345.47.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 22.38 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Barclays assumed coverage on Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target for the company. Daiwa Securities Group decreased their price target on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Cantor Fitzgerald restated a “neutral” rating and issued a $350.00 price target on shares of Amgen in a research note on Wednesday, April 8th. Erste Group Bank restated a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Finally, Leerink Partners restated a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research note on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $353.81.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.